Celaid Therapeutics: Funding, Investors & Team (Sep 2026)
Celaid Therapeutics is a biotech company that develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders.
Celaid Therapeutics has raised $3.6M across 1 funding round on record, the most recent a Series B of $3.6M announced in Oct 2025.
That round is below the $12M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Celaid Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2025.
Celaid Therapeutics Funding Rounds
Celaid Therapeutics Founders and Leadership Team
Contact details for the Celaid Therapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Celaid Therapeutics Funding Compared to Other Biotechnology Startups
Celaid Therapeutics' latest round of $3.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Celaid Therapeutics in Biotechnology and Hongo
Companies Similar to Celaid Therapeutics
Bionto is a biotech startup that is shaping the future of medicine and healthcare through its groundbreaking…
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and…
Captain T Cell is a start-up project that develops T cell-based immunotherapies for cancer patients.
Reprogenix is a groundbreaking medical technology firm
Rion Vet mission is to drive the regenerative medicine revolution.
Oncolab is developing a technology that reduces systemic toxicity and enhances therapeutic efficacy.
Modulight Bio develops an optogenetic platform intended for the treatment of neurological disorders.
Nomax Therapeutics develops a healthcare technology platform to provide therapies for neurodegenerative…
Gregor Diagnostics is a molecular diagnostics company developing a screening test technology for prostate…
Gut Brain Axis Therapeutics is a biotechnology company that offers treatment for Autism Spectrum Disorder…
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal…
iOrganBio is a pioneering cell production platform.
Celaid Therapeutics Funding FAQs
What does Celaid Therapeutics do?
Celaid Therapeutics is a biotech company that develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders.
How much funding has Celaid Therapeutics raised?
Celaid Therapeutics has raised $3.6M across 1 round on record. The most recent is a Series B of $3.6M announced in Oct 2025.
When did Celaid Therapeutics last raise funding?
Celaid Therapeutics' most recent funding round on record is a Series B of $3.6M, announced in Oct 2025.
Who is the CEO of Celaid Therapeutics?
Nobuyuki Arakawa is listed as CEO at Celaid Therapeutics.
Where is Celaid Therapeutics headquartered?
Celaid Therapeutics is based in Hongo, Japan.
How many employees does Celaid Therapeutics have?
Celaid Therapeutics is in the 1-10 employee band.
How does Celaid Therapeutics' funding compare to other Biotechnology startups?
Celaid Therapeutics' latest round of $3.6M is below the $12M median round size for Biotechnology companies on FundedIQ across 27 tracked companies over the last two years.
About FundedIQ's Celaid Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Celaid Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.